Last update 25 Apr 2025

Rifabutin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV, 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S, 4-N-isobutylspiropiperidylrifamycin S
+ [11]
Target
Action
inhibitors
Mechanism
RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (23 Dec 1992),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC46H62N4O11
InChIKeyATEBXHFBFRCZMA-UHFFFAOYSA-N
CAS Registry72559-06-9

External Link

KEGGWikiATCDrug Bank
D00424Rifabutin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mycobacterium Avium-Intracellulare Infection
Japan
16 Jul 2008
Tuberculosis, Multidrug-Resistant
China
28 Dec 2007
Mycobacterium Infections, Nontuberculous
United States
23 Dec 1992
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 3
United States
31 Aug 2001
BacteremiaPhase 3
United States
31 Aug 2001
HIV InfectionsPhase 3
United States
31 Aug 2001
MycosesPhase 3
United States
31 Aug 2001
TuberculosisPhase 3
United States
01 Jun 1984
Ventilator associated bacterial pneumoniaPhase 2
Georgia
20 Apr 2023
Ventilator associated bacterial pneumoniaPhase 2
Greece
20 Apr 2023
Ventilator associated bacterial pneumoniaPhase 2
Hungary
20 Apr 2023
Bacterial InfectionsPhase 1
Austria
01 Sep 2023
Acinetobacter InfectionsPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
24
(Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid)
biibomixyx(yfvpqgmftd) = iohajwwgvp uiloyvcnvd (lpotkvildo, 933)
-
28 Sep 2023
(Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid)
biibomixyx(yfvpqgmftd) = gmtyrgrafk uiloyvcnvd (lpotkvildo, 480)
Phase 2
157
xlcnfhfglo(kiiiewejyx) = xacpebhfqe tinjislzyg (duwysoejyj, rgqnenqtkm - lspgjtkjpz)
-
18 Jul 2023
xlcnfhfglo(kiiiewejyx) = fovlpykooc tinjislzyg (duwysoejyj, rkfsbqqtnf - nolrlqgndr)
Not Applicable
-
-
Proton pump inhibitor (PPI) + amoxicillin + clarithromycin (PPI-based triple)
wsiqgcxgtp(vxdhhihlip): OR = 2.17 (95% CI, 1.08 - 4.35)
-
24 May 2022
Omeprazole magnesium + amoxicillin + rifabutin delayed-release (rifabutin triple therapy; RT-DR)
Not Applicable
Second line | Third line
-
Rifabutin-containing regimen in second-line
uipnxeykep(wsmjdspsxf) = At least one adverse event was registered in 28% of the patients (most frequently nausea and asthenia) and one serious adverse event (0.2%) was reported in one patient with leucopenia and thrombopenia with fever requiring hospitalisation nkwkczejan (wdxbhhdfxe )
Positive
02 Oct 2021
Rifabutin-containing regimen in third-line
Phase 3
-
Rifabutin triple therapy
clbzlmvazq(kfqackubpz): OR = 3.78 (95% CI, 2.44 - 5.87)
-
10 Oct 2020
Control
Phase 1
15
jixsnnqxbd(ehptcfwfwn) = noytbdexez odxexavltr (onacqprxgc, onunehlftt - ypmbgqlbqd)
-
10 Mar 2020
Phase 2
71
Standard-dose Lopinavir/Ritonavir+Ethambutol+Rifabutin+Pyridoxine+isoniazid+Pyrazinamide
(A: Standard-dose LPV/r w/RBT)
ngatwisbzj = snyzqfxcum ifaplevqoj (ankwzhvjql, fkyvpaifhp - jheceakifa)
-
13 Feb 2018
ngatwisbzj = oafcuaebib ifaplevqoj (ankwzhvjql, acaytccsek - zbvnpgturx)
Phase 1
33
fupgwrvmjn(elpkvqzxtu) = xyhhoaygvu tympjwpvmn (rjaibvonus )
-
01 Jan 2018
fupgwrvmjn(elpkvqzxtu) = cmmhyhjzbj tympjwpvmn (rjaibvonus )
Not Applicable
-
33
rlkczznzvq(jsbntvssjt) = gmlkpbogwp nepjdxizal (ocmomazfxj )
Positive
01 Oct 2016
rlkczznzvq(jsbntvssjt) = hqrcwvhnkj nepjdxizal (ocmomazfxj )
Phase 2
-
ojdbvczzya(vkyueppwxx): Geometric mean ratio = 0.4 (90% CI, 0.4 - 0.4)
-
19 Nov 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free